Ischemic injury induces a variety of mechanisms that promote angiogenesis in the injured tissue. This angiogenic environment should, at least in theory, induce the differentiation of PCs into vascular endothelial cells (ECs), but few recruited PCs actually become incorporated into the vasculature and display a true EC phenotype. 6 It is known that undifferentiated PCs are relatively quiescent, relying primarily on anaerobic glycolysis for energy production 7 ; activation (and subsequent differentiation) of the quiescent cells is often accompanied by a metabolic change or switch from anaerobic glycolysis to mitochondrial oxidative phosphorylation (mtOP). 
T he majority of current clinical trials for cardiovascular cell therapy use bone marrow progenitor cells (BM PCs) 1 because they are well characterized and include a subpopulation of endothelial PCs, which play a crucial role in cardiovascular homeostasis. 2 However, despite ample evidence from the literature indicating that the transplanted cells are incorporated into the vasculature and secrete angiogenic growth factors that support the developing microvasculature, 3, 4 the clinical efficacy observed in these trials remains modest 1 ; few of the transplanted (or mobilized endogenous) PCs differentiate into vascular cells to achieve functional integration and long-term engraftment, and this limited potential for differentiation into endothelial-lineage cells is one of the major barriers to the success of PC therapy. 5 
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is largely controlled by pyruvate dehydrogenase kinases 4 and 2 (PDK4/2). 9 PDK4/2 phosphorylate pyruvate dehydrogenase (PDH), which inactivates the PDH complex, and this decline in PDH complex activity limits mtOP. [10] [11] [12] Intriguingly, when the PDK4/2 genes are deleted in hematopoietic stem cells (HSCs), the HSCs are forced to switch from anaerobic glycolysis to mtOP, and this change is associated with a marked increase in the number of mature blood cells and decline in the number of HSCs 9 ; conversely, when mtOP is disrupted by deleting the mitochondrial phosphatase PTPMT1 (protein tyrosine phosphatase localized to the mitochondrion 1), HSC differentiation is blocked, the number of mature blood cells declines, and HSC numbers increase by ≈40-fold. 13 These provocative findings encourage us to hypothesize that the failure of BM PCs to assume an EC identity occurs because these cells are not metabolically primed for differentiation; that is, the cells continue to produce energy primarily through anaerobic glycolysis, which supports quiescence, rather than mtOP, which is required for differentiation, and that priming the metabolic switch in BM PCs at the site of vascular injury may enhance the differentiation of PCs into endothelial-lineage cells and promote cardiovascular repair.
E2F transcription factor 1 (E2F1) is a member of the E2F family transcription factors known for regulating cell proliferation and apoptosis.
14 However, evidence from our laboratory and others suggests that E2F1 is dispensable for vascular growth; rather, loss of E2F1 in mice is protective during ischemic and ischemic reperfusion injuries. [15] [16] [17] Interestingly, E2F1 has recently been recognized as a major regulator of energy metabolism. In skeletal muscle and adipose tissues, E2F1 suppresses the expression of components in the mitochondrial respiratory chain, and E2F1-deficient (E2F1 -/-) mice display elevated exercise endurance and resistance to cold-induced hypothermia. 18 Intriguingly, E2F1 has also been shown to bind to PDK4 promoter and activate PDK4 expression in myoblasts. 19 However, it is unknown whether E2F1 regulates the metabolism and differentiation of BM PCs and whether this regulation is attributable to the beneficial effect of E2F1 deficiency under ischemic injury.
Here, we report that in BM PCs, E2F1 is a potent activator of PDK4/2 gene expression; genetic deletion of E2F1 leads to decreased PDK4/2 expression, increased oxidative metabolism and endothelial differentiation, and enhanced vascular repair after myocardial infarction (MI). Thus, reset of BM PC metabolism via inhibition of E2F1 or enhancement of mtOP may provide a novel strategy for enhancing the effectiveness of cell therapy.
Methods
All materials, methods, and supporting data are available within the article and in the Online Data Supplement.
Mice
The E2F1
-/-and Tie2/LacZ mice were obtained and genotyped as we reported previously. 16, 17 Age-matched male mice were used. Sample sizes were determined by power calculation with 80% power. The investigators responsible for histological analyses were blinded to surgical groups. Mice were randomly assigned to the experimental groups. All animals were bred, maintained, and operated in the Center for 
Novelty and Significance
What Is Known?
• Adult bone marrow progenitor cells (BM PCs) have differentiation potential into endothelial cell lineage; however, little evidence suggests their de novo vasculogenesis in the ischemic tissue.
• The efficacy of cell therapy is modest and attributed to paracrine mechanisms.
• Deletion or inhibition of E2F transcription factor 1(E2F1) is protective of ischemic injury.
• The differentiation of stem/progenitor cells is associated with an increase in oxidative metabolism.
What New Information Does This Article Contribute?
• Deletion of E2F1 in BM PCs augments oxidative metabolism, which promotes endothelial differentiation.
• E2F1 suppresses oxidative metabolism by increasing pyruvate dehydrogenase kinase 4 (PDK4) and PDK2 expression.
• Deletion of E2F1 in BM enhances PC-mediated vasculogenesis and cardiac repair after myocardial infarction.
• Modulation of E2F1-PDK4/2 pathway or oxidative metabolism in BM PCs may enhance the effectiveness of cell therapy.
Clinical outcomes of cell therapy for ischemic heart disease have been unsatisfactory thus far. One of the major barriers to success is that the capacity of de novo vasculogenesis of PCs has not been realized as limited number of BM PCs actually become vascular endothelial cells and incorporated into the vessels. In this study, we found that deletion of the E2F1 transcription factor in BM PCs enhances endothelial differentiation by increased oxidative metabolism and that E2F1 suppresses oxidative metabolism by increasing PDK4 and PDK2 expression. Deletion of E2F1 in the BM enhances PC-mediated vasculogenesis in the infarcted myocardium and improves the cardiac repair and functional recovery. Our findings suggest that the E2F1-PDK4/2 pathway, or oxidative metabolism in general, may serve as a novel target for improving the effectiveness of cardiovascular cell therapy.
Isolation and Culture of BM PCs
BM mononuclear cells (MNCs) were isolated by density gradient centrifugation. 20 Lineage-negative (Lin -) PCs were enriched through a lineage cell depletion kit, followed by an additional step to deplete CD31 + cells (Miltenyi Biotec, Cambridge, MA); the final purity (>95%) and amount of CD31 + cells (<0.2%) were confirmed by flow cytometry. The Lin -PCs were either used freshly or maintained in suspension culture with IMDM (Iscove's modified Dulbecco's medium) plus 10% fetal bovine serum, thrombopoietin (20 ng/mL), stem cell factor (10 ng/mL), and interleukin-3 (6 ng/mL; R & D Systems) as we previously described.
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Oxygen Consumption Rate and Extracellular Acidification Rate Measurements
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of BM PCs were measured with Seahorse XF24 extracellular flux analyzer (Seahorse Bioscience). Briefly, Lin -BM PCs were seeded in 100 μL culture medium at a density of 5×10 5 /well in XF24 24-well cell culture plate coated with BD Cell-Tak (BD Biosciences) and incubated at 37°C for 30 minutes. After cell attachment, an additional 400 μL medium was added to each well and incubated at 37°C overnight. Before analysis, the medium was gently removed and replaced with 500 μL prewarmed specially formulated Seahorse DMEM (Seahorse Bioscience) supplemented with 10 mmol/L glucose (assay medium) and incubated at 37°C without CO 2 for 1 hour. After calibration of the XF24 sensor cartridge, the cell culture plate was placed in the analyzer, and the ECAR and OCR were simultaneously measured. ECAR and OCR rates were normalized to cell numbers.
In Vitro Differentiation Assay
BM-MNCs were cultured on vitronectin-coated flasks in endothelial cell growth medium 2 (EGM-2) supplemented with endothelial growth factor cocktail SingleQuots (Clonetics, San Diego, CA).
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After 4-day culture, nonadherent cells were removed, and new medium was applied. The adherent cells were maintained for a total of 7 days before phenotypic and functional assessments.
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction
Quantitative reverse transcription polymerase chain reaction was performed as we described previously. 20 Primer sequences for genes encoding for Atp5g1, Cox5a, Ndufv1, Sdha, Uqcr, Idh3a, Ucp2, PGK, PDK1-4, E2F1-8, and β-actin were reported in Online Table I . The results were normalized to the mRNA levels of β-actin or 18S.
Western Blotting
Proteins were extracted in cell lysis buffer (Cell Signaling Technology) and analyzed with Western blotting by using rabbit anti-PDK4 antibody (1:500; Abcam), rabbit anti-PDK2 and antiphospho-PDH antibodies (1:250; Santa Cruz), and rabbit anti-β-actin and antiα-tubulin antibodies (1:3000; Cell Signaling Technology). The intensities of protein bands were quantified densitometrically by using the NIH IMAGE software.
Flow Cytometry
BM PC-derived ECs were blocked with mouse Fc blocker, stained with fluorescein isothiocyanate-conjugated antimouse CD31 and phycoerythrin-conjugated antimouse Flk-1 antibodies (BD Biosciences), and analyzed on a FACSCantoII flow cytometer (BD Biosciences), as we described elsewhere.
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Lentiviral Vectors and BM PC Transduction
The vector backbone plasmid LeGo-iC2 (control-mCherry) was purchased from Addgene (Cambridge, MA). The mouse PDK4 cDNA on pCMV6-PDK4 was purchased from OriGene (Rockville, MD) and cloned into LeGo-iC2 to generate LeGo-PDK4 (PDK4-mCherry) by using the EcoRI and NotI restriction sites. To produce lentiviral vectors, the backbone plasmids were cotransfected, separately, with envelope (pMD2.G) and packaging (psPAX2) plasmids 22 into 293FT cells; 2 days later, virus-containing supernatants were collected and concentrated by ultracentrifugation. 22 To infect BM PCs, the lentivirus were applied to the cells (multiplicity of infection: 50) with polybrene (8 µg/mL final concentration). The medium was replaced on the following day, and the cells were cultured for an additional 3 days before fluorescence-activated cell sorter sorting for the transduced cells based on mCherry expression.
BM Transplantation
To evaluate the role of BM E2F1 in the ischemic cardiac repair, BM transplantation was performed to reconstitute the BM of lethally irradiated wild-type (WT) mice with E2F1-knockout/eGFP (enhanced green fluorescent protein)-transgenic (E2F -/-eGFP) or eGPF (control) donor BM-MNCs. 21 Eight weeks after BM transplantation, the engraftment was assessed by fluorescence-activated cell sorter for the proportion of eGFP-expressing peripheral blood MNCs cells isolated from ≈100 μL tail-bleed. The recipients with an engraftment >90% were chosen for surgical induction of MI.
Surgical Induction of MI and Echocardiography
MI was induced in mice by permanent ligation in the middle of the left anterior descending coronary artery. 23 Trans-thoracic 2-dimensional echocardiographic measurements were performed before MI (baseline) and at 7, 14, and 28 days post-MI by using a Vevo 770TM high-resolution ultrasound biomicroscope (VisualSonics Inc, Toronto, Ontario, Canada) and Vevo analysis software (Vevo 2.2.3; VisualSonics Inc). 23 Mice were lightly anesthetized with inhaled 2% isofluorane, and heart rates were maintained at 400 to 500 beats per minute. M-Mode and B-Mode images were recorded, and left ventricular fractional shortening and ejection fraction were calculated. 23 
Histological Assessments
Cardiac tissues were fixed in 4% paraformaldehyde for 4 hours and then snap-frozen. Serial cryosectioning was performed starting at 1 mm below the suture (used to ligate the left anterior descending) moving toward the apex, with 3 consecutive sections per 1 mm to allow for quantitative pathohistological analysis at each level. 23 The Masson Trichrome elastic tissue staining was performed, and infarct size was reported as the ratio of the length of fibrotic area to the length of the left ventricular inner circumference. To evaluate PC endothelial differentiation and capillary density, immunohistochemical staining was performed using fluorescent anti-BS lectin 1 (Vector Laboratories, Inc) and anti-CD31 (Santa Cruz) antibodies 16, 21, 23 ; 3 sections per ischemic heart and 6 fields per section were examined. All surgical procedures and pathohistological analyses were performed by investigators blinded to treatment assignments.
Statistical Analyses
All values are reported as mean±SEM. Two-tailed Student t test was used to compare 2 means. One-way or 2-way ANOVA with a Bonferroni correction was used to compare multiple (>2) means with 1 or 2 independent variables respectively. A P<0.05 was considered significant.
Results
E2F1 Deficiency Increases OCR and Decrease ECAR in BM PCs
We firstly isolated Lin -BM PCs from E2F1 -/-and WT mice and measured OCR at baseline and after sequential treatments with F 1 F 0 ATP synthase inhibitor oligomycin, uncoupler FCCP (carbonyl cyanide-4-[trifluoromethoxy] phenylhydrazone), and electron transport chain blocker antimycin A plus rotenone. Compared with WT PCs, E2F1 -/-PCs displayed a significantly greater OCR; the basal and maximum (FCCP-induced) OCR in E2F1 -/-PCs were elevated by 53.8% and 50.4%, respectively ( Figure 1A and 1B). Treatment with oligomycin or with antimycin A plus rotenone abrogated the differences in OCR between the 2 groups of cells. In contrast, the ECAR level was lowered in E2F1 -/-PCs by 73.5% at baseline and by 83.6% with oligomycin treatment (Figure 1C and 1D ). We then measured the level of lactate, the end product of anaerobic glycolysis, and the activity of glucose-6-phosphate dehydrogenase, a rate-limiting enzyme of the pentose phosphate pathway, in these cells. Consistent with the reduced ECAR level, the lactate level was significantly lower in E2F1 -/-BM PC than in WT cells (Online Figure IA) . The glucose-6-phosphate dehydrogenase activities, however, were similar between the 2 groups of cells (Online Figure IB) . Thus, endogenous E2F1 expression seems to suppress mtOP and promote anaerobic metabolism of pyruvate without altering pentose phosphate pathway in BM PCs.
E2F1 Deficiency and mtOP Elevation Promote the Differentiation of BM PCs Into Endothelial-Lineage Cells
Because increased oxidative metabolism has been linked to PC differentiation, we performed an endothelial differentiation assay by culturing same number of E2F1 -/-and WT BM PCs (CD31 + cell-depleted Lin -BM-MNCs) in the differentiation media for 7 days. A markedly greater proportion ( Figure 1E and 1F) and absolute number (Online Figure II) -/-and WT BM (Online Figure III and Online Table II) . We then isolated CD31 + ECs by fluorescence-activated cell sorter and analyzed their function with a tube formation assay on matrigel; there was no difference in the tube formation activities between E2F1 -/-and WT ECs (Online Figure IV) . In addition, the proliferative capacity, the degree of H 2 O 2 -induced apoptosis, and chemokineinduced migration were all similar between E2F1 -/-and WT PCs (Online Figures V and VI) .
To determine whether loss of E2F1 in BM PCs increase their differentiation in vivo, we performed experiments in which Lin -BM PCs were isolated from Tie2/LacZ;E2F1 -/-or Tie2/LacZ (control) mice, depleted of Tie2 + cells, mixed in Matrigel and subcutaneously implanted into WT mice for 5 days. This model provided us with the opportunity to quantify endothelial differentiation in vivo, defined by the advent of Tie2-driven LacZ expression. Notably, the ratio of X-gal + to total cells was 2× greater in the Matrigel-plugs containing Tie2-LacZ;E2F1 -/-BM PCs than in the Matrigel-plugs containing Tie2-LacZ BM PCs (Online Figure VII) , and these data further support that loss of E2F1 enhances de novo PC endothelial differentiation.
To determine whether the enhanced differentiation capacity of E2F1 -/-PCs is mediated by the altered metabolic activity, we suppressed mtOP in E2F1 -/-and WT BM PCs by adding oligomycin to the differentiation medium. Oligomycin treatment significantly reduced the numbers of CD31 + and Flk-1 + E2F1 -/-cells to levels that did not differ significantly from the numbers of CD31 + and Flk-1 + cells observed in the WT population ( Figure 1F ). These results suggest that the elevation in oxidative metabolism is responsible for the increased endothelial differentiation in E2F1 -/-PCs. Notably, siRNA (small interfering RNA)-mediated acute knockdown of E2F1 in BM PCs also led to a significant increase in mtOP and endothelial differentiation (Online Figure VIII) , confirming that the observations made in E2F1 -/-PCs were not the result of developmental adaptation from the knockout mice. Furthermore, the expression levels of E2F2-8 were similar between E2F1 -/-and WT BM PCs; thus, it is unlikely that other E2F members have contributed to the enhanced mtOP and endothelial differentiation in E2F1 -/-BM PCs (Online Figure IX) .
PDK4 and PDK2 are Downregulated in E2F1 -/-PCs
To identify molecular mechanism by which E2F1 deficiency promotes oxidative metabolism and endothelial differentiation, we analyzed WT and E2F1 -/-BM PCs for the mRNA expression of genes involved in the regulation of glycolysis (Pgk), mitochondria respiration (Atp5g1, Cox5a, Ndufv1, Sdha, and Uqcr), tricarboxylic acid cycle (Idh3a), and uncoupling respiration (Ucp2) but found no significant difference between the 2 groups of cells, except Cox5a expression which was ≈2-fold greater in E2F1
-/-PCs than in WT PCs (Figure 2A ). Because E2F1 has been shown to bind to PDK promoter and PDKs act to limit mtOP by inactivating the PDH complex, we sought to determine whether E2F1 regulates PDK isoenzymes. Although PDK1 and PDK3 expression was similar between the 2 groups of cells, PDK2 and PDK4 mRNA levels were markedly lower in E2F1 -/-PCs than in WT PCs ( Figure 2B ). Our chromatin immunoprecipitation assays confirm that E2F1 occupies the promoter regions of PDK4 and PDK2 that contain the canonical E2F binding site, suggesting that E2F1 likely directly regulates PDK4 and PDK2 transcription (Online Figure X) . Western blotting analyses confirmed that the protein levels of PDK4 and PDK2 were markedly reduced in E2F1 -/-PCs ( Figure 2C and 2D) and so was the level of the PDK4/2's catalytic product, phospho-PDH-E1α ( Figure 2C and 2D) .
Enhancement in mtOP and Endothelial Differentiation in E2F1 -/-PCs Are Mediated by the Reduced PDK4/2 Expression
To determine whether the increased oxidative metabolism of E2F1 -/-PCs is mediated by reduced PDK4/2 expression, we transduced control-mCherry lentivirus in WT and E2F1 -/-BM PCs and PDK4-mCherry lentivirus into E2F1 -/-BM PCs, and 72 hours later, fluorescence-activated cell sorter sorted the transduced cells by mCherry expression (Online Figure XI) . PDK4 overexpression reversed the increase in OCR (at baseline and with FCCP treatment; Figure 2E and 2F) and the decrease in ECAR (at baseline and with oligomycin treatment; Figure 2G and 2H) observed in the E2F1 -/-BM PCs. These results suggest that the increased mtOP in E2F1 -/-BM PCs is likely the result of PDK4/2 reduction. Notably, in the endothelial differentiation assay, PDK4 overexpression also significantly reduced the number of CD31 + and Flk-1 + E2F1 -/-cells and abrogated the difference between E2F1 -/-and WT cells ( Figure 3A and 3B).
E2F1 Deficiency Increases the Proportion of PC-Derived ECs Incorporated in the Ischemic Myocardium
Because the differentiation of recruited BM PCs into endothelial-lineage cells is crucial for de novo vasculogenesis, we evaluated whether E2F1 influences the contribution of BM PCs to vascular growth. The control-mCherry or PDK4-mCherry transduced WT or E2F1 -/-PCs were intravenously injected into WT mice immediately after surgical induction of MI, and 7 days later, the cells that differentiated into endothelial-lineage were assessed by double positive for mCherry expression and CD31 staining. In the infarct border zone (ie, ischemic and ischemic reperfusion area), while the total numbers of recruited mCherry + cells were similar (Online Figure  XII) , the proportion of ECs derived from control-mCherrytransduced E2F1 -/-PCs was 3× greater than ECs derived from control-mCherry-transduced WT PCs ( Figure 3C and 3D) . Notably, the proportion of ECs derived from PDK4-mCherrytransduced E2F1 -/-PCs were markedly lower than ECs from control-mCherry-transduced E2F1 -/-PCs ( Figure 3C and  3D) . Collectively, the results from our in vivo and in vitro experiments suggest that endogenous E2F1 expression impedes 
Ablation of E2F1 in BM PCs Enhances Vascular Growth, Reduces Infarct Size, and Improves Cardiac Function After MI
To determine the role of E2F1 in BM PC-mediated cardiac repair, we isolated BM-MNCs from E2F1
-/-eGFP and WTeGFP mice and transplanted (separately) into lethally irradiated WT mice; 8 weeks later, we surgically induced MI in the recipients with a BM engraftment >90% (Online Figure XIII) . On day 28 post-MI, left ventricular fraction shortening and ejection fraction were significantly greater ( Figure 4A and 4B) , and infarct size was significantly smaller ( Figure 4C and 4D) in mice with E2F1 -/-eGFP BM than in mice with WTeGFP BM. To assess endothelial differentiation and angiogenesis of BM PCs in the ischemic myocardium, MI mice were perfused with lectin-rhodamine to identify function vessels. At the ischemic region, the proportion of GFP+ cells that also incorporated the lectin stain was significantly greater in mice with E2F1 -/-eGFP BM than in mice with WTeGFP BM, which suggests that E2F1 deficiency promotes the differentiation of BM cells into ECs ( Figure 4E and 4F). In addition, mice with E2F1
-/-eGFP BM demonstrated a significantly higher capillary density than mice with WTeGFP BM. Collectively, these results suggest that ablation of E2F1 enhances BM PC-mediated ischemic cardiac repair.
Discussion
In this study, we have identified a novel mechanism by which E2F1, a transcription factor and classic cell cycle regulator, suppresses BM PC oxidative metabolism and endothelial differentiation through expression of the glycolysis enzymes PDK4/2 ( Figure 5 ). Compared with WT BM PCs, E2F1 -/-BM PCs express less PDK4/2, consume more oxygen, and differentiate more readily into endothelial-lineage cells; and all these effects can be reversed by PDK4 overexpression. Remarkably, replacement of WT BM with E2F1 -/-BM in mice significantly increases the contribution of BM PCs to new vessel formation, reduces infarct size, and improves cardiac function after MI. Thus, E2F1-mediated metabolic control impedes adult BM PCs from responding to angiogenic cues in the ischemic myocardial tissue. The experiments described in this report comprise the first investigation of the relationship between the metabolic state and endothelial differentiation in BM PCs. ) PCs were infected with control-mCherry lentivirus or PDK4-mCherry lentivirus, and 3 d later, sorted for the transduced cells based on mCherry expression by fluorescence-activated cell sorter. The sorted PCs were cultured in endothelial PC (EPC) differentiation medium for 7 d and then analyzed by flow cytometry for CD31 and Flk-1 expression (A, representative; B, quantification). n=4 per group. The sorted PCs were intravenously injected to WT mice immediately after surgical induction of myocardial infarction; 7 d later, the mice were euthanized and the cardiac tissues were stained for CD31 (green) to identify the ECs derived from the injected PCs (red; C, representative; D, quantification). n=8 per group. DAPI indicates 4',6-diamidino-2-phenylindole.
Our results are consistent with recent reports, suggesting that metabolism can critically determine the stem cell fate, 9, 24 and that modulation of BM PC metabolism may hold promise for enhancing the effectiveness of cardiovascular cell therapy.
The significance of E2F1 and PDK4/2 in ischemic heart disease has been increasingly recognized in last several years.
25 E2F1 is upregulated in ischemic human hearts, 26 and infarct sizes are remarkably reduced when E2F1 is genetically deleted in murine models of MI 17 and myocardial ischemia reperfusion injury.
15 PDK4/2 are also crucially involved in the pathogenesis of ischemic cardiac injury, and strategies that target PDK4/2 have recently been proposed for the treatment of diabetes mellitus and diabetic cardiomyopathy. [27] [28] [29] Thus, both E2F1 and PDK4/2 are deregulated in patients with ischemic heart disease and diabetes mellitus, and our findings suggest that E2F1-PDK4/2 may be an important metabolic pathway in BM PCs that underlies the functional impairment of endothelial PCs in these patients. 30 This new understanding have implications not just for cell therapy, but also for enhancing the reparative potential of patients' endogenous PC population.
Recently, Blanchet et al 18 have shown that E2F1 deficiency results in an elevated mtOP in skeletal muscle and brown adipose tissues via upregulating genes in the mitochondrial respiratory chain. In this current study, we confirmed that mtOP is also elevated in the E2F1 -/-BM PCs; but intriguingly, this is mediated by reduced PDK4/2 expression, which highlights the tissue specificity of E2F1 targets. Given the largely overlapping phosphorylation sites on PDH between PDK4 and PDK2, 11 it is not surprising that overexpressing PDK4 alone can reverse the effect of both PDK4 and PDK2 downregulation.
Intriguingly, a downregulation of PDK4/PDK2 in E2F1 -/-PCs did not alter the baseline hematopoietic lineage differentiation in the BM as evidenced by our hematopoietic lineage analyses and BM transplantation assays. However, it should be noted that a complete deletion of both PDK4 and PDK2 indeed enhances hematopoietic lineage differentiation. 9 Thus, the degrees of PDK4/PDK2 downregulation needed for endothelial differentiation under angiogenic stress and for hematopoietic lineage differentiation in the BM are different. These observations highlight the difference in the cellular programs of these 2 developmentally related but functionally-distinct cell types. In addition, the site of ischemic injury and the BM stem cell niche are distinct microenvironments, 31 and it is possible that the cellular effect of E2F1 deficiency is differentially counteracted by their environmental signals; this hypothesis, however, is beyond the scope of this current study and remains a subject of our future investigations.
In addition, we and others have previously shown that loss of E2F1 in mice protects limb and cardiac tissues from ischemic and ischemic reperfusion injuries via increased expression of angiogenic factors (including VEGF [vascular endothelial growth factor]) and reduced apoptosis, respectively. [15] [16] [17] Thus, it is likely that both VEGF upregulation (paracrine effect) and PDK2/4 downregulation (autonomous effect) contribute to the enhanced neovascularization in E2F1 -/-animals. However, it should be noted that the exaggerated VEGF upregulation in E2F1 -/-mice occurs primarily during ischemic insults, neither a high vascularity nor perturbation of bone marrow niche was observed in these animals 16 (Online Figure XIV) . More importantly, E2F1 -/-BM PCs display a significantly greater differentiation capacity in a superphysiological concentration of VEGF (ie, much higher than the level of VEGF secreted from cells) in our differentiation assays, which suggests that the E2F1/PDK4-mediated control of PC differentiation is likely independent of VEGF effect. Relative to many other cell types, vascular ECs display a higher rate of glycolysis and lower rate of mitochondrial respiration and increased glycolysis driven by PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) overexpression in ECs enhances vessel sprouting and tip cell function. 32 These observations, although fascinating, should not detract the regulatory role of mitochondrial respiration, which has been associated with the differentiation of various stem/progenitor cells. 33 Importantly, it is still unclear how glycolysis flux affects tip cell function and what intermediate metabolites are involved in the regulation. Conceivably, tip cells and endothelial PCs have different cellular environment; and sprouting and differentiation have different energy demands and require different metabolites-induced signaling pathways.
E2F1 is a classic regulator of cell cycle progression and apoptosis. 34 However, unlike in cancer cells, deletion of E2F1 in BM PCs does not affect proliferation or apoptosis. These results are consistent with our previous observations in ECs that E2F1 is dispensable for EC proliferation and apoptosis while E2F3 is essential for EC growth and angiogenesis. 16, 17, 35 These observations highlight the cell type-dependent actions of E2F family of transcription factors in the cardiovascular system.
Although our data have clearly established the role of E2F1 and the E2F1-PDK4/2 pathway in PC oxidative metabolism and endothelial differentiation, specific metabolites are yet to be identified. Multiple metabolic changes downstream of PDK/PDH, including the metabolic intermediates of mtOP, may potentially contribute to the regulation of PC differentiation and modification of cell phenotype. Emerging evidence now suggests that metabolites can regulate cell function by acting as cofactors or substrates for key enzymes of epigenetic modifications. For example, acetyl-coenzyme A, the fuel of tricarboxylic acid cycle, is a substrate used by histone acetyltransferase enzymes to modify histone tails of chromatins in eukaryotic cells, 36 and nicotinamide adenine dinucleotide, a key electron carrier of mtOP, is consumed by the class III histone deacetylases as a cofactor. 37 In addition, the metabolic changes can alter epigenetic modifications by changing the concentration of those substrates, which eventually lead to phenotype modifications of cells. 38 Furthermore, other products and enzymes associated with mtOP, like ROS (reactive oxygen species) 39 (Online Figure XV) and ATP synthase, 40 may also contribute to the PC differentiation. Importantly, the enhancement of differentiation of E2F1 -/-BM PCs might not be limited to endothelial-lineage; thus, a thorough analysis of potential PC differentiation to other lineage cells are warranted.
In conclusion, our results suggest that the E2F1-PDK4/2 pathway critically controls oxidative metabolism and endothelial differentiation in BM PCs and may be a novel therapeutic target for enhancing the effectiveness of cell therapy for ischemic heart disease.
